EN
Country: EN (China)
Select country/region

Language

  • English
  • Chinese

Message from the Executive Board

Despite all the challenges, 2022 was a year for setting new standards. In particular, this included exceeding the EUR 2 billion sales mark for the first time on December 1. Together, we have achieved a lot and found creative solutions for addressing and overcoming the challenges that arose during the year.

Business performance in 2022 was shaped by geopolitical conflicts, the pandemic, the energy crisis and supply chain disruptions with bottlenecks on procurement markets, primarily for semiconductors. Despite the unfavorable general economic conditions, SICK was able to achieve a positive business performance.

Automation digitalization increased demand for sensor products and applications. The results of the SICK Group’s operations in fiscal 2022 reflected good sales growth, although a disproportionately high rise in expenses due to supply chain disruptions reduced income compared to the previous year. Factory Automation, Logistics Automation, and Process Automation all contributed to our growth.

The ratio between orders received and sales (book-to-bill ratio) was once again high at the end of the past fiscal year, and reflects the opportunities presented by the market, the tough situation with respect to procurement, and supply-side bottlenecks.

To further expand our leading technological position around the world, we invest substantial amounts in research and development. Our financial strength is extremely important here: We are in a very good position to benefit extensively from the ongoing networking and digitalization of industrial production and to help shape this process with our own innovations.

As in past years, SICK spent considerable amounts on R&D activities in the fiscal year 2022, with expenses remaining stable at over 10% of sales. The number of employees working in research and development was increased across the Group as planned, and helped translate innovative ideas into marketable products. Six new start-up initiatives were launched following a business ideas competition in 2022. They presented impressive concepts for digital business models that can generate sales in the world of Industry 4.0.

Further changes were made to the SICK AG Executive Board in 2022. As of July 1, 2022, Nicole Kurek took over as Executive Board member responsible for the People & Culture portfolio at SICK AG. She replaced Dr. Martin Krämer, who was responsible for the Human Resources, Legal & Compliance portfolio and worked for the company for 23 years. Ulrike Kahle-Roth assumed responsibility for the new Supply Chain & Fulfillment Executive Board portfolio at SICK AG as of December 1, 2022. Kahle-Roth has worked at SICK since 2019. She will even more closely interlink activities in Procurement, Operations and Fulfillment. She replaced Dr. Tosja Zywietz, who left the company at the end of the year after almost three years.

In November, Ms. Gisela Sick, the Honorary Chairman of the Supervisory Board and co-founder of the company, celebrated her 100th birthday. With the attitude and values she espouses, Gisela Sick still plays a key role at the family-run company. After the horrors of the Second World War, Ms. Sick and her husband came to only one logical conclusion: SICK products should be developed exclusively for the common good – a principle that still holds true today. This values-based approach is what guides SICK employees and has become firmly incorporated into the business over the years.

Alongside this annual report, we are also publishing our latest magazine: MOMENTUM. We constantly generate momentum by accelerating developments: When our employees’ commitment to projects provides real impetus. When sensor intelligence stimulates innovation to make our customers happy. And when technological progress without sustainability is no longer conceivable.